Posted in M&A / Deals Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis April 7, 2026 BioPharma Dive Gilead s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing. M&A / DealsRead full story